NCT00605306

Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Tolerability of 14-days Treatment With an Inhaled Dose of QMF149 (500/800) in Mild to Moderate Asthmatic Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	indacaterol maleate / mometasone furoate	Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
DRUG	placebo to indacaterol maleate/mometasone furoate	Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.

Timeline

• Start date: 2008-01-01
• Primary completion: 2008-04-01
• Completion: 2008-04-01
• First posted: 2008-01-31
• Last updated: 2013-04-22
• Results posted: 2013-04-22

Locations

3 sites across 1 country: France